Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like FDA Grants Priority Review for Prostrate Cancer Treatment March 19, 2018 GTX Corp Provides Corporate Update And Reports Second Quarter 2017 Financial Results August 13, 2017 2 Biotechs Insiders Just Bought $70 Million Worth of Stock In June 7, 2017
